{4-[3,3-Bis-(4-bromo-phenyl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid | 673479-09-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {4-[3,3-Bis-(4-bromo-phenyl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid
• 英文别名: {4-[3,3-bis-(4-bromophenyl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid；{4-[3,3-bis-(4-bromophenyl)-allylsulfanyl]-2-methylphenoxy}-acetic acid；2-[4-[3,3-bis(4-bromophenyl)prop-2-enylsulfanyl]-2-methylphenoxy]acetic acid
• CAS: 673479-09-9
• 化学式: C₂₄H₂₀Br₂O₃S
• 分子量: 548.295
• InChiKey: KIIKIXRVFFFNJS-UHFFFAOYSA-N

物化性质

• 沸点：
  640.6±55.0 °C(Predicted)
• 密度：
  1.61±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  {4-[3,3-Bis-(4-bromo-phenyl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid 、 3-吡啶硼酸 在 bis-triphenylphosphine-palladium(II) chloride sodium carbonate 作用下， 以 乙醇 、 甲醚 、 水 为溶剂， 反应 0.08h， 以56%的产率得到{4-[3,3-Bis-(4-pyridin-3-yl-phenyl)-allylsulfanyl]-2-methyl-phenoxy}-acetic Acid
  参考文献：
  名称：

  [EN] NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR THERAPEUTICAL USE
  [FR] NOUVEAUX DERIVES D'ACIDE VINYLCARBOXYLIQUE ET LEUR UTILISATION THERAPEUTIQUE

  摘要：

  通用公式（I）的新化合物，这些化合物作为药物组合物的使用，包含这些化合物的药物组合物以及使用这些化合物和组合物的治疗方法。这些化合物可能在治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中有用，特别是PPAR DELTA 亚型。

  公开号：

  WO2004022533A1
• 作为产物：
  描述：

  methyl (4-mercapto-2-methyl-phenoxy)-acetate 在 sodium hydroxide 、 三丁基膦 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 30.0h， 生成 {4-[3,3-Bis-(4-bromo-phenyl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid
  参考文献：
  名称：

  Identification and Synthesis of a Novel Selective Partial PPARδ Agonist with Full Efficacy on Lipid Metabolism In Vitro and In Vivo

  摘要：

  The aim was to identify a novel selective PPAR delta agonist with full efficacy on free fatty acid (FFA) oxidation in vitro and plasma lipid correction in vivo. Using the triple PPAR alpha,gamma,delta agonist 1 as the structural starting point, we wanted to investigate the possibility of obtaining selective PPAR delta agonists by modifying only the acidic part of 1, while holding the lipophilic half of the molecule constant. The structure-activity relationship was guided by in vitro transactivation data using the human PPAR receptors, FFA oxidation efficacy performed in the rat muscle L6 cell line, and in vivo rat pharmacokinetic properties. Compound 7 ([4-[3,3-bis-(4-bromo-phenyl)-allylthio]-2-chloro-phenoxy]-acetic acid) was identified as a selective, partial agonist with good oral pharmacokinetic properties in rat. Chronic treatment of high fat fed ApoB100/CETP-Tgn mice with 7 corrected the plasma lipid parameters and improved insulin sensitivity. These data suggest that selective PPAR delta agonists have the potential to become a novel treatment of dyslipidemia.

  DOI：

  10.1021/jm061202u

文献信息

• Novel compounds, their preparation and use
  申请人：Jeppesen Lone

  公开号：US20050080115A1

  公开（公告）日：2005-04-14

  Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ suptype.

  通用公式（I）的新化合物，这些化合物作为药物组成部分的用途，包含这些化合物的药物组成部分以及使用这些化合物和组成部分进行治疗的方法。这些化合物可能在治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中有用，特别是PPARδ亚型。
• [EN] NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES<br/>[FR] NOUVEAUX COMPOSES TRAITANT LES MALADIES MEDIEES PAR LE PPAR
  申请人：NOVO NORDISK AS

  公开号：WO2004037775A1

  公开（公告）日：2004-05-06

  Novel compounds of the general formula (I), the use of these compounds as pharma-ceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ suptype.

  通用公式（I）的新化合物，这些化合物作为药物组合物的用途，包含这些化合物的药物组合物以及利用这些化合物和组合物进行治疗的方法。这些化合物可能在治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中有用，特别是PPARδ亚型。
• Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
  申请人：Novo Nordisk A/S

  公开号：US07129268B2

  公开（公告）日：2006-10-31

  Novel compounds of the general formula (I), wherein Ar, R1, R2, X1, X2, Y1, Y, and Z are as defined in the specification, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype.

  通用式（I）的新化合物，其中Ar，R1，R2，X1，X2，Y1，Y和Z如规范中所定义，这些化合物的用途作为制药组合物，包含这些化合物的制药组合物以及使用这些化合物和组合物的治疗方法。这些化合物可能在治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中有用，尤其是PPARδ亚型。
• NOVEL COMPOUNDS, THEIR PREPARATION AND USE
  申请人：Jeppesen Lone

  公开号：US20120046350A1

  公开（公告）日：2012-02-23

  Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ suptype.

  本发明提供了一般式（I）的新化合物，这些化合物可用作制药组合物，包括这些化合物的制药组合物以及使用这些化合物和组合物的治疗方法。这些化合物可能有助于治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病，特别是PPARδ亚型。
• Compounds, their preparation and use
  申请人：Novo Novdisk A/S

  公开号：US07091245B2

  公开（公告）日：2006-08-15

  Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ suptype.

  本发明涉及一般式(I)的新化合物，这些化合物可用作制药组合物，制药组合物包括这些化合物，并使用这些化合物和组合物的治疗方法。这些化合物可能对由过氧化物酶体增殖物激活受体（PPAR）介导的疾病和/或预防具有作用，特别是PPARδ亚型。